Company Overview
About Recursion Pharmaceuticals
Recursion Pharmaceuticals (NASDAQ: RXRX) is a computational biology company industrializing drug discovery with AI, founded in 2013 in Salt Lake City, Utah. Built Recursion OS, a vertically integrated platform unifying biology, chemistry, and clinical development. Completed $688M all-stock Exscientia merger (November 2024). Market cap ~$1.62B.
Business Model & Competitive Advantage
2025 revenue $74.7M, net loss $929.8M. Cash: $755M (runway through 2027). Partnerships with Sanofi, Roche, Bayer, and Merck generated $500M+ in payments. In early 2026, Najat Khan became CEO as co-founder Chris Gibson moved to Chairman.
Competitive Landscape 2025–2026
Combined pipeline: 5 clinical programs, 15+ discovery programs. Lead asset REC-4881 (MEK1/2 inhibitor for FAP) showed 53% median polyp reduction in Phase 1b/2. Planning FDA engagement for registration pathway in H1 2026.
Open Positions
Reddit Discussions
Key Differentiators
Strong Challenger
Recursion Pharmaceuticals is an established challenger with significant market presence and competitive offerings in Healthcare Tech.
Growth Stage
Recursion Pharmaceuticals has achieved $688M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Compare Recursion Pharmaceuticals with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Start Comparison →Claim This Profile
Are you from Recursion Pharmaceuticals? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Recursion Pharmaceuticals Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Recursion Pharmaceuticals vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →